This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Celgene, MorphoSys Strike Deal on Blood Cancer Drug

Stocks in this article: CELG SNY JNJ

NEW YORK ( The Deal) - Celgene Corp. (CELG) has made a move to solidify its future in the multiple myeloma space, inking a licensing deal with Germany's MorphoSys AG for its MOR202 drug that could be worth $818 million to MorphoSys.

Munich-based MorphoSys gets an up-front license fee of 70.8 million Euros ($92 million) and Celgene will purchase $60 million worth of new shares of the company, the parties said Thursday.

Multiple myeloma is a blood cell cancer affecting white blood cells that produce antibodies. It's fairly rare, accounting for only about 1% of cancers, but until recently death occurred between one and four years after diagnosis. With newer drugs, such as those developed by Celgene, survival in many with the disease has been extended several years. Celgene, based in Summit, N.J., is a leader in MM treatments with its U.S.-approved brands Thalomid, Revlimid and Pomalyst. MOR202 would offer an option for revenue replacement in that space as those brands lose exclusivity.

The transaction must be cleared by U.S. antitrust authorities under the Hart-Scott-Rodino Act. The price of shares will be determined following that clearance. It will include a premium of at least 15% of the closing price of the shares prior to the parties signing the agreement.

Total value of the transaction could hit $818 million for MorphoSys, which may be entitled to additional development, regulatory and sales milestones plus tiered double-digit royalties on net sales outside a co-promotion territory.

Celgene secures worldwide rights to MOR202 while sharing the rights with MorphoSys to co-promote the drug candidate in Europe if it is approved there. MorphoSys retains 50-50 profit sharing in its co-promotion territory.

MOR202 is a fully human monoclonal antibody targeting CD38 and is in development to treat MM and leukemias. It is now in a Phase 1/2a trial in patients with relapsed/refractory MM. MorphoSys and Celgene will share in the costs of development of the mAb for MM and other indications, with MorphoSys paying one-third of the costs and Celgene two-thirds.

Patients continue to need new options for treatment of the disease, said Mark Alles, executive vice president and global head of hematology and oncology at Celgene. "Strategic investments in next-generation medical innovation make it possible for physicians to turn incurable cancers like MM into chronic, more manageable diseases."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs